MedTrace Logo

Exploration of Neuropathic Pain Induced by Oxaliplatin Electrophysiological Approach

NCT02827916 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-09-06

No results posted yet for this study

Summary

Oxaliplatin is an anticancer agent commonly used in the treatment of colorectal cancer. However, the development of neuropathic pain under treatment limits its use. These are manifested by acute hyperesthesia / distal cold allodynia and chronic course of hypoesthesia.

It is widely reported that these pains are consecutive to hyperexcitability of some ioniques2 channels (mainly sodium and potassium channels). However, the pathophysiological mechanisms of neurotoxicity are multifactorial and still imperfectly described.

Since May 2014, the hospital group Paris Saint Joseph led the pilot study LIPIDOXA whose challenge is to quantify / measure NAION and explained by a biochemical approach, specifically Lipidomics. The CANALOXA study is the logical continuation of LIPIDOXA study insofar design methodology relies heavily on techniques developed for LIPIDOXA study and that the expected results will be complementary to those of LIPIDOXA.

Conditions

  • Peripheric Neuropathy
  • Chemo-induced Neuropathy

Interventions

DEVICE

Assessment of neuropathic pain with theThermotest device

Measure of painful neuropathy with thermotest

DEVICE

Assessment of neuropathic pain with SUDOSCAN device

Measure of painful neuropathy with sudoscan Devices

DEVICE

Assessment of neuropathic pain with the Neuropathic Pain Symptom Inventory.

Measure of painful neuropathy with Neuropathic Pain Symptom Inventory.

Sponsors & Collaborators

  • Fondation Hôpital Saint-Joseph

    lead OTHER

Principal Investigators

  • COUDORE Francois, MD · Fondation Hôpital Saint-Joseph

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-04
Primary Completion
2016-04-13
Completion
2017-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02827916 on ClinicalTrials.gov